We provide services including safety evaluation of pharmaceutical injectables, genotoxicity safety evaluation of drugs, pharmacokinetic studies, pharmacodynamic studies, respiratory toxicology studies, reproductive toxicology studies, bioequivalence assessment of generic drugs, safety and efficacy evaluation of medical devices, non-clinical and clinical safety evaluation of veterinary drugs, drug testing, packaging material testing, and more for pharmaceutical and medical device R&D institutions, research institutes, and pharmaceutical companies.
Technical services
Non-clinical Pharmacokinetic
In vivo pharmacokinetic studies
Animal species: Mouse/Rat/Rabbit/Dog/Crab-eating Macaque/Indian Rhesus Monkey/Miniature Pig/Model Animals, etc. Route of administration: intravenous/oral/subcutaneous/intraperitoneal/muscular/local administration, etc. Biomatrix Collection: Blood/plasma/serum/urine and feces/bile/various tissues Microsampling: one mouse, one PK Detection methods: LC-MS/MS, LC-QTOF, RT-PCR, ELISA, radioisotope labeling, etc. Data Analysis: Phoenix WinNonlin and Gastrol plus are used for PK/PD and PBPK calculations and simulations. Specialized Service: Non-clinical Pharmacokinetic Studies of Radioisotope-Labeled Compounds
Inhibition assays: 1) Reversible inhibition 2) Time-dependent inhibition Metabolic Phenotype Assays: 1) CYP—chemical inhibition and recombinant enzyme methods; 2) UGT—recombinant enzyme method. Enzyme induction: CYP450 enzyme subtypes (1A2, 2B6, and 3A4) Transporter Assay: ABC transporter substrate assays (P-gp and BCRP); vesicle systems or Caco-2 cells; ABC Transporter Substrate Inhibition Assay (P-gp and BCRP): Vesicle System; SLC Transporter Substrate Assays (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, MATE2K) SLC Transporter Inhibition Assays (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, MATE2K)
Metabolic cage collection of urine and feces for LC-MS/MS analysis Rat bile duct cannulation and bile collection for LC-MS/MS analysis. After radiolabeling with 3H/14C isotopes, the radioactivity in feces, urine, and bile is measured (online radioactivity monitoring—HPLC-mass spectrometry). 125I-labeled drug, determination of total radioactivity in feces, urine, and bile
Metabolic Stability: Hepatocytes / Liver S9 / Liver Microsomes Metabolite Identification Assay (Metabolic Species Differences) Metabolite analysis following 3H/14C labeling of compounds
Tissue distribution determination Brain/Blood Ratio Study of the Test Substance Whole blood plasma distribution ratio Plasma Protein Binding: Equilibrium Dialysis Method/Ultrafiltration Membrane Method After administration of 125I-labeled macromolecular drugs, measure the total radioactivity and the precipitated radioactivity in tissues. Determination of radioactivity in tissues after administration of 3H/14C-labeled small-molecule drugs.
Absorption Assessment of Single-Dose or Repeated-Dose Administration Absorption Assessment of Drug Administration via Non-Rodent Double-Crossover and Latin Square Designs Pharmacokinetic-Pharmacodynamic Studies of Biological Products
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681